Acanthoma planoepitheliale hyperkeratoticum, lesions associated with BRAF inhibitor in metastatic melanoma

E-ISSN： 1468-3083|32|2|e83-e84

ISSN： 0926-9959

Source： JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol.32, Iss.2, 2018-02, pp. : e83-e84

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

CANCER, Vol. 121, Iss. 21, 2015-11 ,pp. : 3826-3835

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation‐positive metastatic melanoma, including recognition and management of rare presentations

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 4, 2015-10 ,pp. : 1024-1031

John Wiley & Sons Inc

Access to resources Recommend Favorite

A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 1, 2018-01 ,pp. : 265-269

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

CANCER, Vol. 120, Iss. 11, 2014-06 ,pp. : 1695-1701

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3821-3829

John Wiley & Sons Inc

Access to resources Recommend Favorite